Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate UpdateGlobeNewsWire • 05/15/23
Recent Price Trend in Ocuphire Pharma, Inc. (OCUP) is Your Friend, Here's WhyZacks Investment Research • 05/08/23
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and EyeceleratorGlobeNewsWire • 05/02/23
Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical ProgramsGlobeNewsWire • 04/25/23
Ocuphire Pharma Plunges Following CEO Termination, New Appointment: The Bull, Bear Case - Ocuphire Pharma (NASDAQ:OCUP)Benzinga • 04/21/23
Wall Street Analysts Believe Ocuphire Pharma, Inc. (OCUP) Could Rally 257.14%: Here's is How to TradeZacks Investment Research • 04/21/23
Ocuphire Pharma, Inc. (OCUP) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 04/21/23
Ocuphire Pharma, Inc. (OCUP) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 04/20/23
As Ocuphire Pharma Rally Gathers Steam Post-Results, What Did Investors Initially Miss?24/7 Wall Street • 04/06/23
Does Ocuphire Pharma, Inc. (OCUP) Have the Potential to Rally 323.89% as Wall Street Analysts Expect?Zacks Investment Research • 04/05/23
Here's Why Momentum in Ocuphire Pharma, Inc. (OCUP) Should Keep goingZacks Investment Research • 04/05/23
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate UpdateGlobeNewsWire • 03/30/23
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual MeetingGlobeNewsWire • 03/23/23
Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of MydriasisGlobeNewsWire • 02/13/23
What Makes Ocuphire Pharma, Inc. (OCUP) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 02/06/23
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDAGlobeNewsWire • 01/25/23
Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in PresbyopiaGlobeNewsWire • 01/09/23
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of MydriasisGlobeNewsWire • 12/06/22